Drugs

Relenza (zanamivir) Information

Relenza (zanamivir) is approved for treatment of acute uncomplicated illness due to influenza A and B in patients 7 years of age and older. It is also approved for preventive use (prophylaxis) in patients 5 years of age and older.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program using the contact information at the bottom of this page.

Contact FDA

1-800-332-1088
1-800-FDA-0178 Fax
Report a Serious Problem

MedWatch Online

Regular Mail: Use postage-paid FDA Form 3500

Mail to: MedWatch 5600 Fishers Lane

Rockville, MD 20857

Page Last Updated: 10/23/2014
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.